Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight individuals. The trial assessed the safety, pharmacokinetics, efficacy, ...
An AI-designed obesity drug targeting the GIP receptor shows over 31% weight loss in preclinical tests, raising hopes for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results